| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/AJH.24282 |
| P8608 | Fatcat ID | release_qoocxhk3b5berj4mmeewjxunwu |
| P698 | PubMed publication ID | 26690614 |
| P50 | author | Preetesh Jain | Q41349775 |
| P2093 | author name string | Kanti R Rai | |
| P2860 | cites work | Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 |
| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia | Q24681296 | ||
| New strategies in chronic lymphocytic leukemia: shifting treatment paradigms | Q26828496 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 | ||
| Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia | Q27851685 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Recurrent mutations refine prognosis in chronic lymphocytic leukemia. | Q27853022 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Chronic lymphocytic leukemia | Q28236621 | ||
| Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia | Q28255147 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 | ||
| Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. | Q30768193 | ||
| Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study | Q30843979 | ||
| Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. | Q33374160 | ||
| The evolutionary biography of chronic lymphocytic leukemia | Q43561318 | ||
| Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia | Q44656669 | ||
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 | ||
| Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. | Q46925495 | ||
| B-cell receptor signaling in chronic lymphocytic leukemia. | Q50674847 | ||
| Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. | Q50941921 | ||
| Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. | Q51025698 | ||
| Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. | Q52621343 | ||
| SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. | Q52644149 | ||
| NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. | Q52648282 | ||
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. | Q53061290 | ||
| Advances in the clinical staging of chronic lymphocytic leukemia. | Q53411179 | ||
| The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. | Q53595110 | ||
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 | ||
| Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. | Q54580268 | ||
| Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. | Q54789536 | ||
| Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. | Q55056539 | ||
| Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 | ||
| Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma. | Q55500369 | ||
| Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 | ||
| Non-coding recurrent mutations in chronic lymphocytic leukaemia | Q56996904 | ||
| Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion | Q58041703 | ||
| Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | Q41429394 | ||
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 | ||
| High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 | ||
| Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions | Q42643278 | ||
| Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). | Q43138104 | ||
| A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. | Q43146957 | ||
| Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients | Q43555954 | ||
| Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia | Q33394947 | ||
| Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia | Q33396222 | ||
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma | Q33417117 | ||
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | Q33419580 | ||
| Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia | Q33426511 | ||
| Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. | Q33578875 | ||
| Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia | Q33595764 | ||
| Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium | Q33796183 | ||
| Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease | Q33934606 | ||
| Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients | Q34037828 | ||
| Familial predisposition and genetic risk factors for lymphoma | Q34044984 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| SF3B1 and other novel cancer genes in chronic lymphocytic leukemia | Q34093678 | ||
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial | Q34141305 | ||
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 | ||
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
| Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma | Q34403901 | ||
| Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia | Q34418874 | ||
| Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab) | Q34508322 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 | Q34879367 | ||
| Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations | Q35029461 | ||
| The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells | Q35078248 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial | Q35560022 | ||
| The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. | Q35583403 | ||
| Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia | Q35607285 | ||
| Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes | Q35625192 | ||
| Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia | Q35671227 | ||
| Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. | Q35692395 | ||
| Single-Cell Analysis and Next-Generation Immuno-Sequencing Show That Multiple Clones Persist in Patients with Chronic Lymphocytic Leukemia | Q35768156 | ||
| Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation | Q35820367 | ||
| Clinical staging and prognostic markers in chronic lymphocytic leukemia | Q35869482 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome | Q35906329 | ||
| Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study | Q35953518 | ||
| Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia | Q36135185 | ||
| Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36253983 | ||
| Molecular pathogenesis of chronic lymphocytic leukemia | Q36290321 | ||
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36337598 | ||
| Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia | Q36399593 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia | Q36519986 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications | Q36862781 | ||
| Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia | Q36929831 | ||
| De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience | Q37028638 | ||
| Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses | Q37104775 | ||
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 | ||
| Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness | Q37697850 | ||
| Targeting Bruton's tyrosine kinase in B cell malignancies | Q38198490 | ||
| How does lenalidomide target the chronic lymphocytic leukemia microenvironment? | Q38243771 | ||
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial | Q38424831 | ||
| What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows? | Q38586543 | ||
| The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression | Q38986156 | ||
| CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
| Mutations driving CLL and their evolution in progression and relapse | Q39714436 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. | Q39809953 | ||
| Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. | Q40532403 | ||
| Rituximab dose-escalation trial in chronic lymphocytic leukemia | Q40604465 | ||
| Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. | Q40779596 | ||
| P433 | issue | 3 | |
| P921 | main subject | lymphocyte | Q715347 |
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 330-340 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | Chronic lymphocytic leukemia (CLL)-Then and now | |
| P478 | volume | 91 |
| Q90255204 | A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment |
| Q91962657 | Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy |
| Q92990818 | Can Dendritic Cell Vaccination Prevent Leukemia Relapse? |
| Q38558475 | Chronic lymphocytic leukaemia: a step ahead in the journey toward eradication |
| Q93050531 | Cutaneous manifestation of chronic lymphocytic leukemia: a case report and a literature review |
| Q64091853 | Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact |
| Q94483996 | DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy |
| Q59358761 | Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables |
| Q89497970 | Educational Case: Small Lymphocytic Lymphoma: Diagnostic Features and Prognosis |
| Q88946183 | GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death |
| Q51173647 | HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. |
| Q39010883 | Ibrutinib: A Review in Chronic Lymphocytic Leukaemia |
| Q60949707 | Isotype Specific Assembly of B Cell Antigen Receptors and Synergism With Chemokine Receptor CXCR4 |
| Q54250559 | Low-count monoclonal B-cell lymphocytosis persists after 7 years of follow-up and is associated with a poorer outcome. |
| Q93349257 | Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications |
| Q50502690 | NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. |
| Q48133317 | Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia |
| Q64263337 | Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia |
| Q89600801 | Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry |
| Q89181531 | Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia |
| Q52579907 | Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. |
| Q64949407 | Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia. |
| Q90705663 | Role of circular RNA in hematological malignancies |
| Q55017371 | Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. |
| Q28075683 | The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia |
| Q33688473 | The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia |
| Q90394311 | Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets |
Search more.